AR042917A1 - Dispositivo de liberacion sostenida para la administracion ocular de agentes adrenergicos y uso de agentes adrenergicos para su preparacion - Google Patents

Dispositivo de liberacion sostenida para la administracion ocular de agentes adrenergicos y uso de agentes adrenergicos para su preparacion

Info

Publication number
AR042917A1
AR042917A1 ARP040100201A ARP040100201A AR042917A1 AR 042917 A1 AR042917 A1 AR 042917A1 AR P040100201 A ARP040100201 A AR P040100201A AR P040100201 A ARP040100201 A AR P040100201A AR 042917 A1 AR042917 A1 AR 042917A1
Authority
AR
Argentina
Prior art keywords
adrenergic
sustained release
adrenergic agents
adrenergic agent
agents
Prior art date
Application number
ARP040100201A
Other languages
English (en)
Original Assignee
Control Delivery Sys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Control Delivery Sys Inc filed Critical Control Delivery Sys Inc
Publication of AR042917A1 publication Critical patent/AR042917A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0092—Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/28—Materials for coating prostheses
    • A61L27/34—Macromolecular materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/432—Inhibitors, antagonists
    • A61L2300/434—Inhibitors, antagonists of enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/606—Coatings
    • A61L2300/608—Coatings having two or more layers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/16—Materials or treatment for tissue regeneration for reconstruction of eye parts, e.g. intraocular lens, cornea

Abstract

La presente provee un dispositivo para tratar y/o prevenir la presión intraocular elevada, tal como la asociada con el glaucoma o el uso de corticosteroides, con agentes adrenérgicos. La presente provee dispositivos de liberación sostenida insertables adaptados para mantener una concentración terapéuticamente eficaz de uno o más agentes adrenérgicos durante un período de tiempo prolongado, y el uso de los agentes adrenérgicos para la preparación del dispositivo de liberación sostenida. Reivindicación 1: Un dispositivo para fármaco de liberación sostenida adaptado para la implantación en o adyacente al ojo de un paciente, comprendiendo el dispositivo de administración del fármaco: i) un núcleo de fármaco interior que comprende un agente adrenérgico; ii) un primer recubrimiento sobre la superficie del núcleo del fármaco, que es sustancialmente impermeable al pasaje del agente adrenérgico, que tiene una o más aberturas en el mismo que permiten la difusión del agente adrenérgico, y que es sustancialmente insoluble e inerte en los fluidos corporales y compatible con los tejidos corporales; y iii) uno o más recubrimientos adicionales que son permeables al pasaje del agente adrenérgico, y que son sustancialmente insolubles e inertes en los fluidos corporales y compatibles con los tejidos corporales; donde los recubrimientos primero y adicionales están dispuestos cerca del núcleo de fármaco interior para producir, cuando están implantados, una velocidad de liberación sustancialmente constante del agente adrenérgico del dispositivo.
ARP040100201A 2003-01-24 2004-01-23 Dispositivo de liberacion sostenida para la administracion ocular de agentes adrenergicos y uso de agentes adrenergicos para su preparacion AR042917A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US44249903P 2003-01-24 2003-01-24
US48331603P 2003-06-26 2003-06-26
US48267703P 2003-06-26 2003-06-26
US50197403P 2003-09-11 2003-09-11

Publications (1)

Publication Number Publication Date
AR042917A1 true AR042917A1 (es) 2005-07-06

Family

ID=32831098

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040100201A AR042917A1 (es) 2003-01-24 2004-01-23 Dispositivo de liberacion sostenida para la administracion ocular de agentes adrenergicos y uso de agentes adrenergicos para su preparacion

Country Status (15)

Country Link
EP (1) EP1592408B1 (es)
JP (1) JP2006516618A (es)
KR (1) KR20050118161A (es)
AR (1) AR042917A1 (es)
AT (1) ATE440595T1 (es)
AU (1) AU2004207506B2 (es)
BR (1) BRPI0406879B1 (es)
CA (1) CA2513751C (es)
DE (1) DE602004022776D1 (es)
DK (1) DK1592408T3 (es)
ES (1) ES2332720T3 (es)
MX (1) MXPA05007719A (es)
SI (1) SI1592408T1 (es)
TW (1) TWI356714B (es)
WO (1) WO2004066979A2 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004066980A2 (en) * 2003-01-24 2004-08-12 Control Delivery Systems, Inc. Sustained release device and method for ocular delivery of carbonic anhydrase inhibitors
US20050244463A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
US8425929B2 (en) 2004-04-30 2013-04-23 Allergan, Inc. Sustained release intraocular implants and methods for preventing retinal dysfunction
EP2377569A1 (en) 2004-07-02 2011-10-19 QLT Plug Delivery, Inc. Treatment medium delivery device and methods for delivery of such treatment mediums to the eye using such a delivery device
US8795711B2 (en) * 2006-03-31 2014-08-05 Mati Therapeutics Inc. Drug delivery methods, structures, and compositions for nasolacrimal system
US9173773B2 (en) 2006-06-21 2015-11-03 Johnson & Johnson Vision Care, Inc. Punctal plugs for the delivery of active agents
SG138567A1 (en) * 2006-06-21 2008-01-28 Johnson & Johnson Vision Care Punctal plugs for the delivery of active agents
FR2906712A1 (fr) * 2006-10-09 2008-04-11 France Chirurgie Instr Bouchon meatique a pose simplifiee.
WO2008083118A1 (en) * 2006-12-26 2008-07-10 Qlt Plug Delivery, Inc. Drug delivery implants for inhibition of optical defects
ES2533359T3 (es) * 2007-09-07 2015-04-09 Mati Therapeutics Inc. Núcleos de fármaco para liberación sostenida de agentes terapéuticos
AU2008296872A1 (en) * 2007-09-07 2009-03-12 Qlt Inc. Lacrimal implants and related methods
US20090264477A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc., An Indiana Corporation Beta adrenergic receptor agonists for treatment of pain and/or inflammation
US9949942B2 (en) * 2008-05-09 2018-04-24 Mati Therapeutics Inc. Sustained release delivery of active agents to treat glaucoma and ocular hypertension
US10064819B2 (en) 2008-05-12 2018-09-04 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
TW201012469A (en) * 2008-06-24 2010-04-01 Qlt Plug Delivery Inc Combination treatment of glaucoma
US9095506B2 (en) 2008-11-17 2015-08-04 Allergan, Inc. Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof
EP2376019A1 (en) * 2008-12-19 2011-10-19 QLT, Inc. Substance delivering punctum implants and methods
CN102271632A (zh) * 2009-01-02 2011-12-07 爱尔康研究有限公司 可原位再填充的眼植入物
CN102724951A (zh) 2009-11-09 2012-10-10 阿勒根公司 用于刺激毛发生长的组合物和方法
EP2555749B1 (en) * 2010-04-06 2016-10-26 Allergan, Inc. Sustained-release reservoir implants for intracameral drug delivery
US8349005B2 (en) 2011-01-03 2013-01-08 Masatoshi Murata Method for burying implant to choroid
ES2666857T3 (es) 2011-07-18 2018-05-08 Mor-Research Applications Ltd. Un dispositivo para ajustar la presión intraocular
KR20150119254A (ko) 2013-02-15 2015-10-23 알러간, 인코포레이티드 지속된 약물 전달 임플란트
WO2018231811A1 (en) * 2017-06-13 2018-12-20 EyePoint Pharmaceuticals, Inc. Bioerodible drug delivery devices

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5378475A (en) * 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
US5902598A (en) * 1997-08-28 1999-05-11 Control Delivery Systems, Inc. Sustained release drug delivery devices
US6196993B1 (en) * 1998-04-20 2001-03-06 Eyelab Group, Llc Ophthalmic insert and method for sustained release of medication to the eye
US6375972B1 (en) * 2000-04-26 2002-04-23 Control Delivery Systems, Inc. Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof

Also Published As

Publication number Publication date
DK1592408T3 (da) 2010-01-04
CA2513751C (en) 2012-01-10
ATE440595T1 (de) 2009-09-15
BRPI0406879B1 (pt) 2015-12-22
TW200500099A (en) 2005-01-01
TWI356714B (en) 2012-01-21
EP1592408A2 (en) 2005-11-09
AU2004207506B2 (en) 2009-10-08
SI1592408T1 (sl) 2010-01-29
MXPA05007719A (es) 2005-09-30
WO2004066979A3 (en) 2004-09-16
KR20050118161A (ko) 2005-12-15
EP1592408B1 (en) 2009-08-26
CA2513751A1 (en) 2004-08-12
BRPI0406879A (pt) 2006-01-03
ES2332720T3 (es) 2010-02-11
DE602004022776D1 (de) 2009-10-08
JP2006516618A (ja) 2006-07-06
AU2004207506A1 (en) 2004-08-12
WO2004066979A2 (en) 2004-08-12

Similar Documents

Publication Publication Date Title
AR042917A1 (es) Dispositivo de liberacion sostenida para la administracion ocular de agentes adrenergicos y uso de agentes adrenergicos para su preparacion
CO6400201A2 (es) Suministro liberado sostenido de uno o más agentes
AR048773A1 (es) Sistema de administracion de droga (por ejemplo,dexametasona) para tratar una condicion ocular, implante bio-erosionable de liberacion prolongada comprendido en el anterior y uso de este ultimo para la fabricacion de dicho sistema de administracion de droga
ES2533359T3 (es) Núcleos de fármaco para liberación sostenida de agentes terapéuticos
ATE482001T1 (de) Medizinprodukt mit arzneimittelzufuhrglied
EA200100694A1 (ru) Биосовместимые имплантируемые средства доставки глазного препарата с контролируемым высвобождением и способы их применения
CO6351718A2 (es) Suministro de liberacion sostenida de agentes activos para tratar glaucoma e hipertension ocular
AR048645A1 (es) Tratamientos para el implante ocular de efecto terapeutico prolongado
MX2007002688A (es) Dispositivo para administrar agentes bioactivos y metodo de fabricacion.
WO2006041942A3 (en) Ocular delivery of polymeric delivery formulations
DE60239868D1 (de) Reservoirvorrichtung für die intraokulare arzneimittelabgabe
WO2009076547A8 (en) Implantable drug delivery device and methods for treatment of the bladder and other body vesicles or lumens
ATE421316T1 (de) Herstellung von langzeit- arzneimittelabgabevorrichtungen mit polymeren auf polyurethanbasis
PT1385452E (pt) Dispositivo de administração de fármacos oftálmicos
AR054331A1 (es) Vehiculos de suspension de polioxaester para uso con sistemas de suministro implantables
TW200626178A (en) Loadable polymeric particles for therapeutic and/or diagnostic applications and methods of preparing and using the same
CA2513752A1 (en) Sustained release device and method for ocular delivery of carbonic anhydrase inhibitors
WO2005011772A3 (en) Implantable or insertable medical devices containing radiation-treated polymer for improved delivery of therapeutic agents
BR0205990A (pt) Um sistema implantável de liberação unidirecional de agentes terapêuticos para tecidos
RU2010149066A (ru) Способы доставки лекарственных средств, структуры и композиции для носослезной системы
AR039131A2 (es) Metodo para administrar un agente farmaceuticamente activo a un tejido a ser tratado en un cuerpo y metodo para administrar un agente farmaceuticamente activo a un ojo
WO2017176886A8 (en) IMPLANTABLE DEVICES FOR THE DELIVERY OF DRUGS BY THE EYE
US11931538B2 (en) Therapeutic delivery device
ATE456391T1 (de) Abgabe eines therapeutischen mittels
ES2244361T1 (es) Uso del acetato de anecortave para la proteccion de la agudeza visual en pacientes con degeneracion macular asociada a la edad.

Legal Events

Date Code Title Description
FB Suspension of granting procedure